Business
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals ...
About this update from Sunshine Biopharma Inc.
[{"type":"text","content":"FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 annual report on Form 10-K on Tuesday, April 1, 2025. The following are highlights of the report:","length":401,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue in 2024 grew to $34.9 million, a 45% increase over 2023 revenue of $24.1 million.","length":89,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":89,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Completed an underwritten public offering of approximately $10 million in gross proceeds for expansion of sales operations.","length":123,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":123,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Launched 13 new generic prescription drugs, 4 under cross-licensing agreements and 9 under distribution agreements.","length":115,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":115,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Received regulatory approval from Health Canada for marketing of the oncology drug NIOPEG®, a biosimilar of NEULASTA®.","length":118,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":118,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Announced publication of groundbreaking research results in the Journal of Medicinal Chemistry (J. Med. Chem. 2024, 67, 13681−13702) demonstrating the superior efficacy of Sunshine Biopharma's new Coronavirus PLpro inhibitor. The study showcases a PLpro inhibitor with sub-micromolar potency and robust in vivo efficacy in a mouse model of SARS-CoV-2 infection. This peer-reviewed research marks an important milestone in Sunshine Biopharma's ongoing efforts to develop proprietary therapies in critical disease areas.","length":526,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":526,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Announced completion of mouse model studies providing proof-of-concept f...